Back to search
Hypertension Pulmonary Secondary Heart Failure
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hypertension Pulmonary Secondary Heart Failure trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hypertension Pulmonary Secondary Heart Failure trials you may qualify forPH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.
This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with seco…
Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjec…